Anti-C9 antibody (ab118902)
Key features and details
- Rabbit polyclonal to C9
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-C9 antibody
See all C9 primary antibodies -
Description
Rabbit polyclonal to C9 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant Human C9 protein.
-
Positive control
- Human Small Intestine, Vessels Human Placenta methanol-fixed HepG2 Raji cell lysate
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 10% Glycerol (glycerin, glycerine), Tris glycine -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab118902 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/3000. Predicted molecular weight: 62 kDa.
|
|
IHC-P |
Use a concentration of 10 µg/ml.
|
|
ICC/IF |
1/100 - 1/200.
|
Notes |
---|
WB
1/500 - 1/3000. Predicted molecular weight: 62 kDa. |
IHC-P
Use a concentration of 10 µg/ml. |
ICC/IF
1/100 - 1/200. |
Target
-
Function
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. -
Sequence similarities
Belongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 1 TSP type-1 domain. -
Post-translational
modificationsThrombin cleaves factor C9 to produce C9a and C9b.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore. - Information by UniProt
-
Database links
- Entrez Gene: 735 Human
- Omim: 120940 Human
- SwissProt: P02748 Human
- Unigene: 654443 Human
-
Alternative names
- ARMD15 antibody
- C9 antibody
- C9 deficiency antibody
see all
Images
-
Immunohistochemistry analysis (Formalin-Fixed, Paraffin-Embedded) of Human Small Intestine, Vessels stained with ab118902 at 10 µg/ml
-
Immunohistochemistry analysis (Formalin-Fixed, Paraffin-Embedded) of Human Placenta stained with ab118902 at 10 µg/ml
-
Immunofluorescence analysis of methanol-fixed HepG2, using ab118902 at 1:200 dilution.
-
Anti-C9 antibody (ab118902) at 1/500 dilution + Raji cell lysate at 30 µg
Predicted band size: 62 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab118902 has not yet been referenced specifically in any publications.